Waregem (Belgium) / Rotterdam (The Netherlands)[1], 17 June 2011 (7:30 am) – Pursuant to Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, Arseus announces today that 20,749 new shares have been issued as a result of the exercise of warrants. These newly issued shares are entitled to dividend as of the 2011 financial year.
The number of Arseus shares with voting rights is 31,216,888. The total number of voting rights (denominator) is 31,216,888. The share capital is € 320,023,050.35.
On 17 June 2011, there are 1,191,601 outstanding warrants under Warrant Plan 1 and Warrant Plan 2. The total number of voting rights obtainable upon the exercise of these warrants is 1,191,601.
For more information:
Constantijn van Rietschoten
Director of Corporate Communications
+31 88 33 11 222 (office)
+31 6 536 91 585 (mobile)
constantijn.van.rietschoten@arseus.com
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
Arseus Profile
Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in Europe, the US and Brazil. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical IT-solutions.
The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
[1] This press release was sent out by Arseus NV and Arseus BV.
Please open the link below for the full press release: